NFJ Investment Group LLC Makes New $2.46 Million Investment in Supernus Pharmaceuticals, Inc. $SUPN

NFJ Investment Group LLC bought a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 52,790 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,455,000. NFJ Investment Group LLC owned about 0.09% of Supernus Pharmaceuticals at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Rockefeller Capital Management L.P. lifted its stake in Supernus Pharmaceuticals by 354.8% in the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock valued at $42,000 after buying an additional 660 shares during the last quarter. Torren Management LLC bought a new stake in Supernus Pharmaceuticals during the fourth quarter worth approximately $49,000. Hantz Financial Services Inc. boosted its stake in Supernus Pharmaceuticals by 73.3% during the fourth quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock valued at $54,000 after buying an additional 458 shares in the last quarter. Global Retirement Partners LLC acquired a new position in shares of Supernus Pharmaceuticals in the 2nd quarter worth approximately $64,000. Finally, Vestcor Inc bought a new position in shares of Supernus Pharmaceuticals in the third quarter valued at $67,000.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Wall Street Zen downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Zacks Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 6th. Finally, Cantor Fitzgerald boosted their price objective on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Supernus Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $62.83.

Supernus Pharmaceuticals Stock Down 3.4%

Shares of SUPN opened at $45.85 on Friday. The stock has a market cap of $2.67 billion, a price-to-earnings ratio of -23.88, a P/E/G ratio of 0.87 and a beta of 0.56. Supernus Pharmaceuticals, Inc. has a 12 month low of $42.45 and a 12 month high of $59.68. The company has a 50-day moving average price of $46.74 and a two-hundred day moving average price of $48.82.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). The company had revenue of $219.06 million for the quarter, compared to the consensus estimate of $205.31 million. Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The firm’s revenue was up 32.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.40 earnings per share. Equities research analysts expect that Supernus Pharmaceuticals, Inc. will post 1.97 EPS for the current fiscal year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.